Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development
Through the development of epigenetic biomarkers, EpiSwitch™ can help pharmaceutical companies to:
- REDUCE the risk, cost and time to market for therapeutic development programmes
- GAIN significant insights into disease mechanisms, to support the personalisation of medicine
- PERSONALISE therapeutics to patients, to ensure better clinical outcomes
Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.